H3K23ac Epigenetic Programming Reverses Immune Aging: Breakthrough from West China Hospital
West China Hospital, Sichuan University | Published in Nature Cell Biology, May 26, 2026
What if the creeping decline of the immune system that accompanies every human life was not an irreversible fate, but a programmable switch that could be turned back? In a landmark study published in Nature Cell Biology on May 26, 2026, a team from Sichuan University’s West China Hospital has answered that question with striking clarity.
The Discovery
The research team discovered a specific epigenetic mechanism — H3K23 acetylation — that drives hematopoietic stem cells (HSCs) toward a degenerative fate. More importantly, they demonstrated that small molecule intervention can reverse that fate, opening an entirely new frontier in aging medicine.
Key Findings
The Meg3+ HSC Subset
Through single-cell multi-omics profiling, the team identified a previously unrecognized subpopulation of HSCs marked by expression of the long non-coding RNA Meg3. In young organisms, Meg3+ HSCs constitute a small minority. With aging, this subset expands substantially, coming to dominate the HSC landscape.
Meg3+ HSCs carry a built-in bias: when called upon to differentiate, they preferentially produce myeloid cells and megakaryocytes, rather than the lymphocytes essential for adaptive immunity.
The Molecular Mechanism
The team uncovered a multi-step signaling cascade connecting inflammatory signals to epigenetic reprogramming:
Inflammatory signals → p65 activation → KAT6A recruitment → H3K23ac deposition → TRIM24 binding → PU.1 enhancement → myeloid-biased differentiation → immune aging
- Inflammatory signals activate the NF-κB transcription factor p65
- p65 recruits KAT6A (histone acetyltransferase) to specific genomic loci
- KAT6A acetylates histone H3 at lysine 23 (H3K23ac) at defined genomic regions
- TRIM24 recognizes H3K23ac and amplifies the myeloid differentiation program
- PU.1 enhancement drives HSCs toward megakaryocyte and myeloid output
The Reversal: Restoring Youthful Immune Function
When the H3K23ac program was pharmacologically disrupted in aged mice:
- The Meg3+ HSC subset stopped expanding
- Hematopoietic output shifted back toward balanced lineage distribution
- Myeloid overproduction was reduced
- Lymphoid output was restored
- Treated aged mice showed improved immune responses
Clinical Significance
Vaccine Responses in the Elderly
The weakened adaptive immune response in immunosenescence is the primary reason that influenza, COVID-19, pneumococcal, and shingles vaccines are significantly less effective in the elderly. By restoring balanced lymphoid output from HSCs, interventions targeting the H3K23ac axis could enhance vaccine efficacy in older adults.
Chronic Inflammation (Inflammaging)
Excess myeloid cells contribute to the systemic inflammatory state underlying atherosclerosis, type 2 diabetes, neurodegenerative diseases, and frailty. H3K23ac-targeted interventions could address the root cause of inflammaging at the stem cell level.
Hematological Malignancies
Myeloid-biased HSCs are the cells of origin for age-associated hematological cancers, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Reversing the H3K23ac program could serve a cancer-preventive function.
Bone Marrow Transplantation
Ex vivo modulation of the H3K23ac program in donor HSCs before transplantation could potentially improve outcomes when older donors must be used.
Research Team
This work emerged from the National Key Laboratory of Biotherapy and Cancer Center at West China Hospital, Sichuan University — one of China’s most prominent medical research institutions and the largest single-site hospital in the world.
Principal Investigators:
- Professor Zhang Huiyuan
- Professor Hu Hongbo
- Professor Dai Lunzhi
First Authors: Wei Ni, Zhan Huiwen, Deng Yujun, Liu Min, Xiao Yao
The publication in Nature Cell Biology (impact factor >21) represents a milestone for Chinese biomedical research in aging epigenetics.
Broader Implications
This study demonstrates that aging is not merely damage accumulation — it involves active epigenetic programming. The H3K23ac axis is a defined, stepwise molecular program that can be interrupted or reversed.
The discovery that small molecule intervention can reverse immune aging brings this work closer to clinical translation than many fundamental aging discoveries. Future studies will address the safety of long-term H3K23ac modulation, the durability of reversal effects, and translation from mouse to human biology.
Sources:
- Wei Ni et al. “Epigenetic programming by H3K23ac defines lineage fate of Meg3+ haematopoietic stem cells and drives immune ageing.” Nature Cell Biology, May 26, 2026.
- West China Hospital, Sichuan University — Academic News, May 2026.